A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Study summary

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCalderasib and Pembrolizumab (+) Berahyaluronidase alfa

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 26, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 3

Interventional

Where is it offered?221 U.S. locations

Locations may change over time.

Who runs it?Merck Sharp & Dohme LLC

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Merck Sharp & Dohme LLC
Interventions being studied: Drug: Calderasib; Biological: Pembrolizumab (+) Berahyaluronidase alfa; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Biomarkers

KRAS→

Treatment approach

Immunotherapy→Targeted therapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

The main inclusion criteria include but are not limited to the following:
Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c
If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART)

Reasons someone may not be able to joinExclusion criteria

The main

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Central Alabama Research ( Site 0108)Birmingham, Alabama
University of Connecticut Health Center ( Site 0130)Farmington, Connecticut
Stamford Hospital ( Site 0126)Stamford, Connecticut
Mount Sinai Cancer Center ( Site 0137)Miami Beach, Florida
Low Country Cancer Care ( Site 0156)Savannah, Georgia
Indiana University Health Arnett Cancer Center ( Site 0116)Lafayette, Indiana
New England Cancer Specialists ( Site 0139)Westbrook, Maine
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0152)Hackensack, New Jersey
New York Oncology Hematology, P.C. ( Site 0119)Albany, New York
Wilmot Cancer Institute ( Site 0141)Rochester, New York
St. Charles Health System, Inc ( Site 0146)Bend, Oregon
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111)Lancaster, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 26, 2026. Always confirm current availability with the study team.

View original record ↗